Table 1. Characteristics of included studies 1 .
| Author | Year | Study Size (Male, %) | Mean Age, y | Prevalence (%) | Time Interval | Selection | Slices | Contrast Material | Reference Standard | mPAP | SPAP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bartalena | 2008 | 39(36.4%) | 59 | 34.6 | 0-86d | Confirmed PH | 16 | Iomeron | V/Q,CTPA | Unclear | Unclear |
| He | 2012 | 49(43%) | 43.3 | 44.7 | 7d | Suspected CTEPH | 16 or 64 | Unclear | DSA | 52.77±18.31 | 1474.66±671.16 |
| Dournes | 2014 | 14(35%) | 67.1 | 35 | 2.0±3.8d | Confirmed PH | DECT | Xenetix 350 | V/Q | Unclear | Unclear |
| Tunariu | 2007 | 85(37.4%) | 42 | 34.8 | 48h-10d | Confirmed PH | Unclear | Unclear | DSA,V/Q,CTPA | Unclear | Unclear |
| Sugiura | 2013 | 16(36%) | 59.2 | 100 | 2d-2w | Suspected CTEPH | 320 | Iomeron | DSA | 42.2±9.9 | 696±274 |
| Reichelt | 2009 | 13(48%) | 59 | 89 | 2d-2w | Suspected CTEPH | 64 | Imeron | DSA,V/Q | 46±8 | 763±345 |
| Ley | 2012 | 13(54.2%) | 58 | 100 | 3d | Suspected CTEPH | 40 or 64 | Imeron | DSA | 42±10 | Unclear |
| Soler | 2011 | 5(55.6%) | 52.8 | 100 | Unclear | Confirmed CTEPH | 4 to 64 | Unclear | DSA | 40±8 | 450±178 |
| Nakazawa | 2011 | 35(67%) | 57.7 | 100 | 2.5d | Suspected CTEPH | DECT | Unclear | DSA | Unclear | Unclear |
| Bergin | 1997 | Unclear | Unclear | 87 | Unclear | Suspected CTEPH | Unclear | Ioversol | DSA | Unclear | Unclear |
| Zhang | 2013 | Unclear | 49 | 100 | 10d | Confirmed CTEPH | 64 | Unclear | DSA | Unclear | Unclear |
1mPAP: mean PAP; sPAP: standard PAP.